Aromatase inhibitors should be first-line treatment for certain type of breast cancer

Women with the type of breast cancer normally treated with tamoxifen could instead benefit from a class of drugs called aromatase inhibitors, conclude authors of a fast-track study published online by THE LANCET.

Tamoxifen therapy for five years after surgery is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, its use is associated with several side effects including endometrial cancer and blood-clotting disorders. The ATAC study is an international collaboration which compared the safety and efficacy of tamoxifen with anastrozole alone and the combination of both drugs for 5 years. The 3-year analysis of these data were encouraging, suggesting that anastrozole could be a future treatment option (see Lancet 2002; 359: 2131-39).

Published today are the 5-year follow-up results of the ATAC study. They show how anastrozole, compared with tamoxifen: increased disease-free survival by over 10%; increased the time to disease recurrence by around 20%; reduced cancer spreading (distant metastases) by 14%, and reduced cancer occurring on the other breast by over 40%.

Fewer women given anastrozole stopped taking the tablets early compared with women given tamoxifen; anastrozole was associated with fewer side effects although bone fractures and joint pain were more common than among women given tamoxifen.

Lead investigator Anthony Howell (Christie Hospital NHS Trust, Manchester, UK) comments: "Results from studies evaluating aromatase inhibitors after 23 years or 5 years of adjuvant tamoxifen, compared with continuing tamoxifen, suggest that it is reasonable to switch patients currently on tamoxifen to an aromatase inhibitor. However, these new data from the ATAC trial suggest that it is not appropriate to wait to start an aromatase inhibitor. The higher rates of recurrence (especially in years 13), and the increased numbers of adverse events and treatment withdrawals associated with tamox

Contact: Joe Santangelo

Page: 1 2

Related medicine news :

1. Aromatase inhibitors: A promising new treatment for endometriosis
2. COX-2 inhibitors associated with blood pressure elevation
3. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
4. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk
5. Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors
6. Breast cancer may be uniquely sensitive to inhibitors of PI3K pathway
7. Researchers debate recreational use of PDE-5 inhibitors
8. ACE inhibitors not needed for many heart disease patients, according to new study
9. HIV-1 protease inhibitors: Effective against malaria?
10. Mechanism found that protects aggressive melanoma from angiogenesis inhibitors
11. Lupus discovery may pave way to better-designed COX-2 inhibitors

Post Your Comments:

(Date:10/17/2019)... ... October 17, 2019 , ... Dr. Parsa Mohebi, the ... Angeles and Beverly Hills, is reminding patients interested in undergoing a hair transplant that ... , According to Dr. Mohebi, “The holidays are a time for friends and family ...
(Date:10/15/2019)... Va. (PRWEB) , ... October 15, 2019 , ... ... Complying with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, October ... recent Instructions for Use (IFU) guidance have on new drug applications and biologics ...
(Date:10/11/2019)... ... October 11, 2019 , ... Inland Detox, Inc. has just moved ... location has incredible views of the Temecula Valley and it’s the perfect place for ... facility offers both private rooms as well as double occupancy rooms, a 2nd home ...
(Date:10/10/2019)... , ... October 10, 2019 , ... ... Annual Conference, Nutrition 21 was excited to hear the significant results of an ... blood flow impact of Nitrosigine®. The clinical study poster entitled “The Acute Effects ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Amir HagShenas of Silicon ... Jose, CA experience relief from this common and treatable condition. Dr. HagShenas’ goal is ... adults from living with uncomfortable symptoms, including tender and bleeding gums, and to prevent ...
Breaking Medicine News(10 mins):
(Date:10/19/2019)... ... ... Hospital M&A activity held steady with 21 transactions in both the second and ... quarter was down 20% compared with the same period in 2018, when 25 deals ... $5.0 billion, a 291% increase. Year over year, Q3:19 spending was down 41% versus ...
(Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... ... a patient receiving the right treatment before it progresses further. With many patients ... resources that can help their correct identification of skin cancer be extremely valuable. ...
(Date:10/11/2019)... ... 11, 2019 , ... The 'W' Initiative, a flagship women ... Health Month. The plans are aimed at improving community awareness on health issues ... to health checks and encouraging healthy lifestyle habits. , Slated to run all ...
Breaking Medicine Technology:
Cached News: